Overview

An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness and safety of CNTO 1275 (ustekinumab) in patients with psoriatic arthritis.
Phase:
Phase 2
Details
Lead Sponsor:
Centocor, Inc.
Treatments:
Antibodies, Monoclonal
Ustekinumab